Coherus Oncology (CHRS) Goodwill & Intangibles (2014 - 2026)

Coherus Oncology (CHRS) has 13 years of Goodwill & Intangibles data on file, last reported at $45.6 million in Q1 2026.

• For the quarter ending Q1 2026, Goodwill & Intangibles fell 13.9% year-over-year to $45.6 million; the trailing twelve-month figure through Mar 2026 stood at $45.6 million (down 13.9% YoY), and the FY2025 full-year result was $46.2 million, down 13.81% from the prior year.
• Goodwill & Intangibles retreated to $45.6 million in Q1 2026, from $46.2 million in the prior quarter.
• In the past five years, Goodwill & Intangibles ranged from a high of $71.7 million in Q4 2023 to a low of $3.6 million in Q1 2022.
• A 5-year average of $36.2 million and a median of $46.5 million in 2023 frame the typical range for Goodwill & Intangibles.
• Across the five-year window, Goodwill & Intangibles soared 1108.45% in 2023 and slipped 25.15% in 2024, its largest moves.
• Tracing CHRS's Goodwill & Intangibles over 5 years: stood at $5.9 million in 2022, then soared by 1108.45% to $71.7 million in 2023, then fell by 25.15% to $53.6 million in 2024, then retreated by 13.81% to $46.2 million in 2025, then fell by 1.35% to $45.6 million in 2026.
• Business Quant data shows CHRS's Goodwill & Intangibles at $45.6 million in Q1 2026, $46.2 million in Q4 2025, and $49.5 million in Q3 2025.